Cargando…
Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as apoptosis, senescence, or DNA repair. In support of this hypothesis, we have prev...
Autores principales: | Knappskog, Stian, Berge, Elisabet O., Chrisanthar, Ranjan, Geisler, Stephanie, Staalesen, Vidar, Leirvaag, Beryl, Yndestad, Synnøve, de Faveri, Elise, Karlsen, Bård O., Wedge, David C., Akslen, Lars A., Lilleng, Peer K., Løkkevik, Erik, Lundgren, Steinar, Østenstad, Bjørn, Risberg, Terje, Mjaaland, Ingvild, Aas, Turid, Lønning, Per E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528784/ https://www.ncbi.nlm.nih.gov/pubmed/26004085 http://dx.doi.org/10.1016/j.molonc.2015.04.008 |
Ejemplares similares
-
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012) -
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
por: Yndestad, Synnøve, et al.
Publicado: (2017) -
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011) -
Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007) -
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
por: Chrisanthar, Ranjan, et al.
Publicado: (2008)